Torrance, California, USA – According to the latest study from MarkWide Research Duchenne Muscular Dystrophy Treatment Market indicates that the CAGR will be 10.62% between 2022 and 2030, which is the projected growth rate.

Duchenne muscular dystrophy (DMD), also known as Duchenne muscular atrophy (DMA), is a rare genetic disorder characterized by progressive muscle weakness and degeneration caused by changes in a protein called dystrophin. A recessive disease associated with X chromosomes and predominantly affecting males, the condition also affects female carriers.

Despite the fact that women are generally unaffected, some may have a milder form of the disease (“manifest carriers”), such as: B. mild muscle weakness, cramps and heart changes. Because dystrophin is absent from muscle cells, they are fragile, easily damaged, and most people affected by DMD will need a wheelchair by the time they reach adulthood. DMD patients between the ages of 19 and 25 are exposed to serious life-threatening conditions such as cardiomyopathy and breathing difficulties, which if left untreated eventually lead to death.


  • Key factors driving the global Duchenne muscular dystrophy market include the introduction of novel drugs, disease-modifying therapies, strong support from various companies in the development of new drugs, and patient advocacy support in the approval process of new drugs and therapies.
  • A major breakthrough in the treatment of Duchenne muscular dystrophy is likely to come as a result of the development of mutation-specific therapies.
  • As new drugs and therapies are developed, drug developers are focused on targeting newborns, young children and even end-stage DMD patients who have the disease.
  • Due to the rapid development of Duchenne muscular dystrophy therapeutics in recent years, significant advances have been made in this area.
  • That…


Source story